Skip to Main Content

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade

Conditions

Phase I

Phase I

What is the purpose of this trial?

The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2752 in patients with relapsed/refractory solid tumor malignancies or lymphoma.

  • Trial with
    Moderna Therapeutics, Inc.
  • Start Date
    06/24/2019
  • End Date
    07/31/2020
Trial Image

For more information about this study, contact:

Ingrid Palma

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/09/2019
  • Study HIC
    #2000023871